Overexpression of DDX43 mediates MEK inhibitor resistance through RAS upregulation in uveal melanoma cells

Molecular Cancer Therapeutics

Volumn 13, Issue 8, 2014, Pages 2073-2080

  Ambrosini, Grazia ^a   Khanin, Raya ^a   Carvajal, Richard D ^a   Schwartz, Gary K ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARRY 142866; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN DDX43; PROTEIN KINASE B; RAS PROTEIN; RNA HELICASE; SELUMETINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; DDX43 PROTEIN, HUMAN; DEAD BOX PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; TUMOR PROTEIN;

ARTICLE; CANCER RESISTANCE; CELL VIABILITY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MELANOMA CELL; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; UVEA MELANOMA; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION; GENETICS; LIVER TUMOR; MELANOMA; METABOLISM; PATHOLOGY; SECONDARY; TUMOR CELL LINE; UVEA TUMOR;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL SURVIVAL; DEAD-BOX RNA HELICASES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; LIVER NEOPLASMS; MAP KINASE KINASE KINASES; MELANOMA; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; UP-REGULATION; UVEAL NEOPLASMS;

EID: 84905666986     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0095     Document Type: Article

References (47)

1. Strickland D, Lee JA. Melanomas of eye: stability of rates. Am J Epidemiol 1981;113:700-02. (Pubitemid 11065971)
2. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am 2005;18:75-84. (Pubitemid 40348812)
3. Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein AM, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. British J Cancer 2005;92:2032-8. (Pubitemid 40897426)
4. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599-602.
5. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. The New England J Med 2010;363:2191-9.
6. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Investig Ophthalmol Visual Sci 2008;49:5230-4.
7. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991;98:383-9;.
8. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993;72:2219-23. (Pubitemid 23280150)
9. Patel M, Smyth E, Chapman PB, Wolchok JD, Schwartz GK, Abramson DH, et al. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res 2011;17:2087-100.
10. Yonekawa Y, Kim IK. Epidemiology and management of uveal melanoma. Hemat/Oncol Clin North Am 2012;26:1169-84.
11. Ambrosini G, Pratilas CA, Qin LX, Tadi M, Surriga O, Carvajal RD, et al. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK-resistance. Clin Cancer Res 2012;18:1-10.
12. Carvajal RD AG, Wolchok JD, Chapman PB, Dickson MA, D'Angelo SP, et al. Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma. J Clin Oncol 2012;30(suppl; abstr 8598).
13. Carvajal RD SJ, Quevedo F, Milhem MM, Joshua AM, Kudchadkar RR, et al. Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM). J Clin Oncol 2013;31 (suppl; abstr CRA9003).
14. Little AS, Balmanno K, Sale MJ, Smith PD, Cook SJ. Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. Biochem Society Trans 2012;40:73-8.
15. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Science Signal 2010;3:ra84.
16. Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Science Signal 2011;4:ra17.
17. Wang Y, Van Becelaere K, Jiang P, Przybranowski S, Omer C, Sebolt-Leopold J. A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia 2005;7:336-47. (Pubitemid 40664223)
18. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7.
19. Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Dis 2013;3:350-62.
20. Martelange V, De Smet C, De Plaen E, Lurquin C, Boon T. Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res 2000;60:3848-55. (Pubitemid 32204577)
21. Adams SP, Sahota SS, Mijovic A, Czepulkowski B, Padua RA, Mufti GJ, et al. Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia 2002;16:2238-42. (Pubitemid 35331839)
22. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, San Jose-Eneriz E, et al. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. Haematologica 2007;92:153-62.
23. Fuller-Pace FV. DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation. Nucleic Acids Res 2006;34:4206-15. (Pubitemid 44542200)
24. Glisovic T, Bachorik JL, Yong J, Dreyfuss G. RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett 2008;582:1977-86.
25. Linder P, Jankowsky E. From unwinding to clamping - the DEAD box RNA helicase family. Nature Rev Molec Cell Biol 2011;12:505-16.
26. Jarmoskaite I, Russell R. DEAD-box proteins as RNA helicases and chaperones. WIREs RNA 2011;2:135-52.
27. Robert F, Pelletier J. Perturbations of RNA helicases in cancer. WIREs RNA 2013;4:333-49.
28. Mathieu MG, Knights AJ, Pawelec G, Riley CL, Wernet D, Lemonnier FA, et al. HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides. Cancer Immunol Immunother 2007;56:1885-95. (Pubitemid 47512610)
29. Linley AJ, Mathieu MG, Miles AK, Rees RC, McArdle SE, Regad T. The helicase HAGE expressed by malignant melanoma-initiating cells is required for tumor cell proliferation in vivo. J Biol Chem 2012;287:13633-43.
30. Griewank KG, Yu X, Khalili J, Sozen MM, Stempke-Hale K, Bernatchez C, et al. Genetic and molecular characterization of uveal melanoma cell lines. Pigment Cell Melanoma Res 2012;25:182-7.
31. Ambrosini G, Musi E, Ho AL, de Stanchina E, Schwartz GK. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Mol Cancer Ther 2013;12:768-76.
32. Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opinion Pharmacol 2005;5:350-6. (Pubitemid 40932036)
33. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011;17:989-1000.
34. Ambrosini G, Pratilas CA, Qin LX, Tadi M, Surriga O, Carvajal RD, et al. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin Cancer Res 2012;18:3552-61.
35. Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012;22:668-82.
36. Chen X, Wu Q, Tan L, Porter D, Jager MJ, Emery C, et al. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene 2013 Oct 21. [Epub ahead of print].
37. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nature Rev Mol Cell Biol 2008;9:517-31. (Pubitemid 351881844)
38. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994;370:527-32. (Pubitemid 24264918)
39. Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. MEK in cancer and cancer therapy. Pharmacol Ther 2014;141:160-71.
40. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008;14:342-6. (Pubitemid 351226098)
41. Little AS, Smith PD, Cook SJ. Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene 2013;32:1207-15.
42. Poulikakos PI, Solit DB. Resistance to MEK inhibitors: should we cotarget upstream? Sci Signal 2011;4:pe16.
43. Das Thakur M, Stuart DD. The evolution of melanoma resistance reveals therapeutic opportunities. Cancer Res 2013;73:6106-10.
44. Abdelhaleem M. Over-expression of RNA helicases in cancer. Anticancer Res 2004;24:3951-3. (Pubitemid 40468691)
45. Chan S. A-FTMA, McArdle S, Moseley P, Johnson C, Andrew R. HAGE (DDX43) protein expression as an independent biomarker of poor clinical outcome of breast cancer (BC) and potential as a therapeutic target for ER-negative BC. J Clinical Oncol 2012;30 (suppl; abstr 1013).
46. Cruciat CM, Dolde C, de Groot RE, Ohkawara B, Reinhard C, Korswagen HC, et al. RNA helicase DDX3 is a regulatory subunit of casein kinase 1 in Wnt-beta-catenin signaling. Science 2013;339:1436-41.
47. Camats M, Guil S, Kokolo M, Bach-Elias M. P68 RNA helicase (DDX5) alters activity of cis- and trans-acting factors of the alternative splicing of H-Ras. PloS ONE 2008;3:e2926.